Archive · 18 Aug 2026
Lord's Mark Industries Unveils ₹1,550 Crore Healthcare Expansion Plan
Lord's Mark Industries is a big Indian company that makes medical tests and also makes energy from renewable sources.
They have announced a big plan to help sick people in India.
The company wants to earn at least ₹1,550 crore by the year 2027, which is more than they earn now.
They plan to open special cancer hospitals in smaller cities like Vapi and Solapur.
They will also bring a new kind of cancer treatment called CAR-T cell therapy to India, so more patients can afford it.
The company wants to set up 50 kidney dialysis centers where people can get treatment when their kidneys are not working well.
They are also making medical test equipment in India and selling it to countries like the UK and Switzerland.
The company will split its energy business into a new company called Lords Shakti Power Limited.
This way, the healthcare part of the business can grow on its own.
The leaders hope this will help more people get good healthcare in India.
Lord's Mark Industries targets consolidated revenue of at least ₹1,550 crore in FY2027, with PAT of at least ₹178 crore at an 11.4% margin.
The board proposes demerging the Renewable Energy and LED business into Lords Shakti Power Limited by March 2027, with Lord's Mark holding 60%.
The company signed an exclusive agreement to bring CAR-T cell therapy to India across five centers, starting with Mumbai and Bangalore by March 2027.
New subsidiary Lords Mark Medicure Limited will launch an oncology hospital network in tier-2 cities, beginning with two pilot 70-bed hospitals in Vapi and Solapur.
Lords Mark Industries UK Limited was incorporated as the first Indian company registered under the India-UK Free Trade Agreement, with an NHS approval application submitted.
- Who
- Lord's Mark Industries Limited, led by Managing Director Sachidanand Upadhyay
- What
- Announced a strategic expansion across global healthcare, advanced diagnostics and oncology, alongside a proposed demerger of its renewable energy division
- When
- Announced today, with FY2027 financial targets and a planned demerger by March 2027
- Where
- India (including Mumbai, Bangalore, Vapi and Solapur) and European markets including the UK and Switzerland
- Why
- To optimize capital allocation, expand patient access to cancer care and diagnostics, and open developed-market channels for its Indian-made medical products
- Company
- Lord's Mark Industries Limited
- FY2027 Revenue Target
- At least ₹1,550 crore (over 20% growth from FY2026)
- FY2027 PAT Target
- At least ₹178 crore at an 11.4% margin
- Proposed Demerger
- Renewable Energy and LED business into Lords Shakti Power Limited by March 2027; Lord's Mark to hold 60%
- CAR-T Cell Therapy
- Exclusive agreement with a global manufacturer; five centers in India starting with Mumbai and Bangalore by March 2027
- Oncology Hospitals
- Two pilot 70-bed hospitals in Vapi and Solapur via Lords Mark Medicure Limited, supported by a planned ₹200 crore debt raise in December 2026
- Dialysis Centers
- 50 company-operated centers across India by March 2027 using proprietary RENALOS machines
- UK Entity
- Lords Mark Industries UK Limited, first Indian company registered under the India-UK Free Trade Agreement; NHS approval application submitted